The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer

<b>Background:</b> Glutathione, along with its related enzymes, constitutes a key antioxidant defense mechanism against oxidative stress and cancer formation in the body. Among urological malignancies, bladder cancer ranks second following prostate cancer. Oxidative stress has significant involvement in the development and prognosis of bladder cancer. This investigation aimed to examine the impact of glutathione on prognosis in patients with non-muscle-invasive bladder cancer. <b>Methods:</b> This study included 98 patients with high grade non-muscle-invasive bladder cancer who had undergone intravesical Bacillus Calmette-Guérin therapy and 30 healthy controls with no history of uroepithelial carcinoma of the bladder. The patients with bladder cancer were evaluated in three subgroups. Group 1 consisted of 41 patients who did not experience recurrence during follow-up, Group 2 included 28 patients who had recurrent tumors, and Group 3 consisted of 29 patients who progressed to muscle-invasive stages. Blood samples were collected from all participants. Blood levels of reduced, oxidized, and total glutathione were measured spectrophotometrically. <b>Results</b>: Reduced glutathione levels significantly differed among the groups (<i>p</i> < 0.001), attributed to the control group exhibiting higher reduced glutathione levels compared with Groups 1, 2, and 3 (<i>p</i> < 0.001). There were no significant differences in reduced glutathione levels between Groups 1 and 2, Groups 1 and 3, or Groups 2 and 3 (<i>p</i> > 0.05). Total glutathione levels varied significantly among the groups (<i>p</i> < 0.001), with the control group having higher levels than Groups 1, 2, and 3 (<i>p</i> < 0.001). No significant differences were detected between any of the paired patient groups in terms of total glutathione levels (<i>p</i> > 0.05). Regarding oxidized glutathione levels, the difference was statistically significant (<i>p</i> < 0.001), with the control group showing lower levels than the remaining three groups (<i>p</i> < 0.001). Paired comparisons revealed no significant differences in oxidized glutathione levels (<i>p</i> > 0.05). <b>Conclusions:</b> This study revealed that glutathione had an effect on the emergence of bladder cancer but did not affect its prognosis. Nevertheless, we recommend that future studies with larger bladder cancer patient cohorts should be conducted to comprehensively determine the impact of glutathione on the prognosis of this cancer.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2024-09-15
DOI
https://doi.org/10.3390/jcm13185483
Citations
2
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
1.15
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer

Sertaç Çimen, Özcan Erel, Abdurrahim İmamoğlu, Gamze Gök et al.
2 citations
Journal of Clinical Medicine
Bladder and Urothelial Cancer Treatments
1.15
article

The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer

Sertaç Çimen, Özcan Erel, Abdurrahim İmamoğlu, Gamze Gök, Alper Gök, Hasan Nedim Göksel Göktuğ, Tarık Küçük
article en
2 citations

Abstract

<b>Background:</b> Glutathione, along with its related enzymes, constitutes a key antioxidant defense mechanism against oxidative stress and cancer formation in the body. Among urological malignancies, bladder cancer ranks second following prostate cancer. Oxidative stress has significant involvement in the development and prognosis of bladder cancer. This investigation aimed to examine the impact of glutathione on prognosis in patients with non-muscle-invasive bladder cancer. <b>Methods:</b> This study included 98 patients with high grade non-muscle-invasive bladder cancer who had undergone intravesical Bacillus Calmette-Guérin therapy and 30 healthy controls with no history of uroepithelial carcinoma of the bladder. The patients with bladder cancer were evaluated in three subgroups. Group 1 consisted of 41 patients who did not experience recurrence during follow-up, Group 2 included 28 patients who had recurrent tumors, and Group 3 consisted of 29 patients who progressed to muscle-invasive stages. Blood samples were collected from all participants. Blood levels of reduced, oxidized, and total glutathione were measured spectrophotometrically. <b>Results</b>: Reduced glutathione levels significantly differed among the groups (<i>p</i> < 0.001), attributed to the control group exhibiting higher reduced glutathione levels compared with Groups 1, 2, and 3 (<i>p</i> < 0.001). There were no significant differences in reduced glutathione levels between Groups 1 and 2, Groups 1 and 3, or Groups 2 and 3 (<i>p</i> > 0.05). Total glutathione levels varied significantly among the groups (<i>p</i> < 0.001), with the control group having higher levels than Groups 1, 2, and 3 (<i>p</i> < 0.001). No significant differences were detected between any of the paired patient groups in terms of total glutathione levels (<i>p</i> > 0.05). Regarding oxidized glutathione levels, the difference was statistically significant (<i>p</i> < 0.001), with the control group showing lower levels than the remaining three groups (<i>p</i> < 0.001). Paired comparisons revealed no significant differences in oxidized glutathione levels (<i>p</i> > 0.05). <b>Conclusions:</b> This study revealed that glutathione had an effect on the emergence of bladder cancer but did not affect its prognosis. Nevertheless, we recommend that future studies with larger bladder cancer patient cohorts should be conducted to comprehensively determine the impact of glutathione on the prognosis of this cancer.

Journal of Clinical MedicineVol. 13(18)
Bilkent University (TR), Memorial Ankara Hospital (TR), Sağlık Bilimleri Üniversitesi (TR), Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi (TR), Ankara Bilkent City Hospital (TR)
Good health and well-being
Openalex Percentile: Top 20%
Bladder and Urothelial Cancer Treatments
1.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.